ppara

ppara

Pathway Diagram

```mermaid
flowchart TD
PPARA["PPARA<br/>Peroxisome Proliferator<br/>Activated Receptor Alpha"]

PPARGC1A["PPARGC1A<br/>PGC-1alpha<br/>Metabolic Coactivator"]
gemfibrozil["Gemfibrozil<br/>PPAR Agonist<br/>Drug"]
Wy14643["Wy14643<br/>PPAR Agonist<br/>Compound"]
JMJD3["JMJD3<br/>Histone Demethylase"]

TFEB["TFEB<br/>Transcription Factor<br/>EB"]
autophagy["Autophagy<br/>Cellular Clearance<br/>Process"]
MAP1LC3B["MAP1LC3B<br/>LC3B<br/>Autophagy Marker"]

APP["APP<br/>Amyloid Precursor<br/>Protein"]
Abeta["Abeta<br/>Amyloid Beta<br/>Plaques"]

AD_prevention["Alzheimer's Disease<br/>Prevention"]
inflammation["Inflammation<br/>Reduction"]
metabolic["Metabolic<br/>Regulation"]
anxiety["Anxiety<br/>Reduction"]

PPARGC1A -->|"activates"| PPARA
gemfibrozil -->|"activates"| PPARA
Wy14643 -->|"activates"| PPARA
JMJD3 -->|"interacts with"| PPARA

PPARA -->|"regulates"| TFEB
PPARA -->|"regulates"| autophagy
PPARA -->|"activates"| MAP1LC3B

PPARA -->|"regulates"| APP
PPARA -->|"reduces"| Abeta

PPARA -->|"prevents"| AD_prevention
PPARA -->|"reduces"| inflammation
PPARA -->|"regulates"| metabolic
PPARA -->|"inhibits"| anxiety

TFEB -->|"enhances"| autophagy
autophagy -->|"clears"| Abeta
MAP1LC3B -->|"mediates"| autophagy

style PPARA fill:#006494
style PPARGC1A fill:#4a1a6b
style gemfibrozil fill:#1b5e20
style Wy14643 fill:#1b5e20
style TFEB fill:#4a1a6b
style autophagy fill:#1b5

ppara

Pathway Diagram

<div class="infobox infobox-gene">
<div class="infobox-header">PPARA</div>
<div class="infobox-content">
<div class="infobox-row"><strong>Full Name:</strong> Peroxisome Proliferator-Activated Receptor Alpha</div>
<div class="infobox-row"><strong>Symbol:</strong> PPARA (NR1C1)</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 22q13.31</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> 5465</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000186951</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q07869</div>
<div class="infobox-row"><strong>Protein Class:</strong> Nuclear receptor, ligand-activated transcription factor</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Alzheimer's Disease, Parkinson's Disease, ALS, Dyslipidemia, Type 2 Diabetes</div>
</div>
</div>

Overview

PPARA (Peroxisome Proliferator-Activated Receptor Alpha) encodes a ligand-activated transcription factor belonging to the nuclear receptor superfamily. Located on chromosome 22q13.31 with NCBI Gene ID 5465, PPARA is primarily expressed in tissues with high fatty acid catabolism, including liver, heart, skeletal muscle, and kidney. However, it is also expressed in the brain, where it plays critical roles in neuroprotection, anti-inflammatory responses, and metabolic regulation.

PPARA regulates genes involved in peroxisomal and mitochondrial fatty acid oxidation, lipid transport, and inflammation. It responds to endogenous ligands including fatty acids and their derivatives, as well as synthetic agonists such as fibrate drugs (fenofibrate, gemfibrozil). The receptor has emerged as a significant therapeutic target for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [ALS](/diseases/als), where impaired lipid metabolism and chronic neuroinflammation are key pathological features.

Gene and Protein Structure

Gene Organization

The PPARA gene spans approximately 85 kb on chromosome 22q13.31 (positions 46,160,000-46,245,000 on GRCh38) and contains 8 exons. The gene produces multiple transcript variants through alternative splicing, with the major isoform encoding a 468-amino acid protein.

Protein Topology

The PPARA protein contains characteristic nuclear receptor domains:

• N-terminal activation domain (AF-1): Ligand-independent activation function, contains phosphorylation sites
• DNA-binding domain (DBD): Two zinc finger motifs recognizing PPAR response elements (PPREs)
• Hinge region: Contains nuclear localization signals and regulatory sequences
• Ligand-binding domain (LBD): Large hydrophobic pocket binding fatty acids and fibrates; contains AF-2
• C-terminal domain: Involved in dimerization and coactivator recruitment

Signaling Mechanisms

PPARA activates transcription through:

Non-genomic signaling: PPARA can also signal through:

• MAPK pathway activation
• PI3K/Akt signaling
• Direct protein-protein interactions with transcription factors

Expression Pattern

Peripheral Tissue Distribution

PPARA shows highest expression in:

• Liver: Highest expression, central role in fatty acid metabolism
• Heart: Supports myocardial fatty acid oxidation
• Skeletal muscle: Enables exercise-induced fatty acid oxidation
• Kidney: Metabolic regulation
• Brown adipose tissue: Thermogenesis

Brain Expression

Within the central nervous system, PPARA is expressed in:

• Neurons: Particularly in cortex, hippocampus, cerebellum
• Astrocytes: High expression, supports astrocytic lipid metabolism
• Microglia: Modulated expression in response to inflammation
• Oligodendrocytes: Supports myelin lipid turnover

Regulation

PPARA expression is regulated by:

• Nutritional state: Upregulated during fasting (increased fatty acids)
• Circadian rhythms: Expression follows daily metabolic cycles
• Inflammatory signals: Upregulated by anti-inflammatory cytokines
• Developmental stage: Higher expression during myelination

Physiological Functions

Lipid Metabolism

PPARA is a master regulator of fatty acid metabolism:

Peroxisomal beta-oxidation:

• Upregulates enzymes for very-long-chain fatty acid oxidation
• Handles branched-chain fatty acids
• Produces hydrogen peroxide (detoxified by catalase)

• Increases carnitine palmitoyltransferase expression
• Enhances fatty acid import into mitochondria
• Supports ATP production from fats

• Increases expression of fatty acid transport proteins (FATP, CD36)
• Regulates apolipoprotein expression
• Controls lipoprotein metabolism

Anti-inflammatory Effects

PPARA exerts potent anti-inflammatory actions:

Transrepression: PPARA inhibits NF-κB and AP-1 signaling:

• Represses pro-inflammatory gene transcription
• Reduces cytokine production (TNF-α, IL-1β, IL-6)
• Dampens immune cell activation

• Increases IκB expression
• Promotes IL-10 production
• Enhances antioxidant enzyme expression

Neuroprotection

In the nervous system, PPARA provides neuroprotection through:

• Reducing excitotoxicity
• Promoting mitochondrial function
• Enhancing antioxidant defenses
• Modulating glial responses

Role in Neurodegenerative Diseases

Alzheimer's Disease

PPARA dysfunction contributes to [Alzheimer's disease](/diseases/alzheimers-disease) through multiple mechanisms:

Amyloid metabolism: PPARA activation affects Aβ handling:

• Increases expression of Aβ-degrading enzymes (neprilysin, IDE)
• Enhances microglial Aβ clearance
• Reduces Aβ production through APP processing modulation

• Reduces microglial activation
• Decreases pro-inflammatory cytokine levels
• Limits complement activation

• Enhances neuronal fatty acid oxidation
• Improves mitochondrial function
• Reduces oxidative stress

• Reduce amyloid plaques in APP/PS1 mice
• Improve cognitive performance
• Protect synaptic function

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), PPARA provides neuroprotection:

Dopaminergic neuron survival: PPARA activation:

• Protects substantia nigra neurons from oxidative stress
• Improves mitochondrial complex I activity
• Reduces MPTP/6-OHDA toxicity

• Modulates aggregation pathways
• Enhances autophagy-mediated clearance
• Reduces neurotoxicity

• Reduces dopaminergic neuron loss
• Limits neuroinflammation spread

Amyotrophic Lateral Sclerosis (ALS)

PPARA involvement in [ALS](/diseases/als) includes:

Metabolic dysfunction: ALS patients show:

• Altered lipid metabolism
• PPARA expression changes in motor neurons
• Energy deficit in affected tissues

• Gemfibrozil showed promise in SOD1 mice
• Protect motor neurons
• Extend survival in preclinical models

Multiple Sclerosis

PPARA plays roles in demyelinating diseases:

• Regulates oligodendrocyte differentiation
• Modulates immune cell function
• May enhance remyelination

Therapeutic Implications

Fibrates

FDA-approved fibrate drugs targeting PPARA:

• Fenofibrate: Most studied in neurodegeneration
• Gemfibrozil: Used in ALS preclinical studies
• Clofibrate: Earlier generation, less specific

Selective PPARA Agonists

Novel selective agonists in development:

• Gevogaren (MET-100: In Phase II for AD)
• Pemexelstat: In development for ALS

Combination Therapy

PPARA agonists may combine well with:

• Acetylcholinesterase inhibitors
• Anti-amyloid antibodies
• Other nuclear receptor agonists (PPARγ, RXR)

Key Publications

See Also

• [Peroxisome Biology](/mechanisms/peroxisome-pathway)
• [Nuclear Receptor Signaling](/mechanisms/nuclear-receptor-pathway)
• [Lipid Metabolism in Neurodegeneration](/mechanisms/lipid-metabolism-dysfunction)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
• [ALS Mechanisms](/diseases/als)

External Links

• [NCBI Gene: PPARA](https://www.ncbi.nlm.nih.gov/gene/5465)
• [UniProt: PPARA](https://www.uniprot.org/uniprot/Q07869)
• [HGNC: PPARA](https://www.genenames.org/data/hgnc_data.php?hgnc_id=9202)
• [OMIM: PPARA](https://www.omim.org/entry/170998)
• [Allen Brain Atlas: PPARA expression](https://human.brain-map.org/)
• [PubMed: PPARA neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=PPARA+Alzheimer+Parkinson+ALS)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ppara discovered through SciDEX knowledge graph analysis: